Brii Biosciences Limited
BRIBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.11 | 0.11 | -0.00 |
| FCF Yield | -56.25% | -54.18% | -13.41% | -11.48% |
| EV / EBITDA | 0.76 | -4.17 | -7.07 | -8.02 |
| Quality | ||||
| ROIC | -15.33% | -17.70% | -16.20% | -18.28% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.73 | 3.22 | 1.01 | 0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.10% | -81.18% | -14.37% | 66.10% |
| Free Cash Flow Growth | 41.56% | -1.27% | 27.82% | -118.10% |
| Safety | ||||
| Net Debt / EBITDA | 2.43 | 2.89 | 2.34 | 4.70 |
| Interest Coverage | 0.00 | -1,101.82 | -603.81 | -519.55 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 10,342.46 | 81.66 | 23.59 |